Does low riboflavin (vitamin B2) raise homocysteine by impairing MTHFR function?

The scientific evidence strongly supports the claim that riboflavin (vitamin B2) serves as an essential cofactor for the methylenetetrahydrofolate reductase (MTHFR) enzyme, and that low riboflavin status directly leads to elevated plasma total homocysteine (tHcy) levels.

Mechanistic explanations

• Cofactor Role: Methylenetetrahydrofolate reductase (MTHFR) is a flavin adenine dinucleotide (FAD)-dependent enzyme. Cellular riboflavin (vitamin B2) is the direct precursor to FAD, which acts as a tightly bound prosthetic group essential for stabilizing the enzyme's conformation, preventing subunit dissociation, and maintaining catalytic activity.
• Genetic Stabilization: The relationship is highly pronounced in individuals with the common C677T (Ala222Val) polymorphism. This variant decreases MTHFR's affinity for FAD, making the enzyme thermolabile and prone to inactivation. Increasing intracellular FAD via riboflavin intake stabilizes this variant structure and rescues its enzymatic function.

Clinical evidence and implications

• Homocysteine Regulation: When riboflavin status is low, MTHFR stability declines, limiting the production of 5-methyltetrahydrofolate needed to remethylate homocysteine back to methionine.
• Epidemiological Insights: Large-scale cohorts, including the Framingham Offspring study and Irish population trials, show that riboflavin status is an independent predictor of circulating tHcy. In individuals with the MTHFR 677TT genotype, adequate riboflavin levels effectively attenuate or completely abolish the genotype-associated elevation in tHcy, even under suboptimal folate conditions.
• Age-Related Relevance: For a 68-year-old male, maintaining adequate riboflavin is a highly practical strategy to manage vascular and cognitive risks associated with age-related hyperhomocysteinemia.

Bottom line

• Riboflavin is the dietary precursor to the FAD cofactor required to stabilize and activate the MTHFR enzyme. A low riboflavin status impairs homocysteine remethylation, leading to elevated homocysteine levels—an effect that is highly pronounced in individuals with the MTHFR C677T polymorphism but is easily reversible with adequate riboflavin intake.